{
    "code": "60000948",
    "url": "https:\/\/info.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=60000948",
    "time": "2020-06-26 06:04:58",
    "許可證字號": "衛部菌疫輸字第000948號",
    "註銷狀態": "已註銷",
    "註銷日期": "109\/04\/13",
    "註銷理由": "未展延而逾期者",
    "製造許可登錄編號": "",
    "有效日期": "107\/10\/25",
    "發證日期": "102\/10\/25",
    "許可證種類": "菌　疫",
    "舊證字號": "",
    "醫療器材級數": "",
    "通關簽審文件編號": "DHA06000094804",
    "中文品名": "瑞樂靶注射劑",
    "英文品名": "Ristova Solution for IV infusion",
    "適應症": "非何杰金氏淋巴瘤\r\n用於復發或對化學療法有抗性之低惡度B-細胞非何杰金氏淋巴瘤。\r\n併用CVP化學療法用於未經治療之和緩性(組織型態為濾泡型）B細胞非何杰金氏淋巴瘤的病人。\r\n併用CHOP或其他化學療法用於CD20抗原陽性之瀰漫性大型B細胞非何杰金氏淋巴瘤。\r\n用於做為濾泡性淋巴瘤患者對誘導療法產生反應之後的維持治療用藥。\r\n類風濕性關節炎：\r\n與methotrexate併用，適用於治療曾接受一種(含)以上之腫瘤壞死因子(TNF)抑制療法治療但效果不彰，或無法耐受的活動性類風濕性關節炎成人患者。\r\n瑞樂靶（Ristova）與methotrexate併用，經X光檢查已證實可減緩關節結構受損的進展。\r\n慢性淋巴球性白血病\r\n瑞樂靶（Ristova）適用於與fludarabine及cyclophosphamide併用，做為CD20陽性慢性淋巴球性白血病(CLL)患者的第一線用藥。\r\n瑞樂靶（Ristova）適用於與化學療法併用，做為復發\/頑固性的CD20陽性慢性淋巴球性白血病病患的治療用藥。\r\n肉芽腫性血管炎( Granulomatosis with Polyangiitis, Granulomatosis with Polyangiitis, GPA)(Wegener’s肉芽腫症)及顯微多發性血管炎(Microscopic Polyangiitis, MPA)： \r\n瑞樂靶（Ristova）與葡萄糖皮質素(glucocorticoids)併用，適用於治療成人之肉芽腫性血管炎(GPA，亦稱為韋格納肉芽腫症)及顯微多發性血管炎(MPA)。",
    "劑型": "270注射劑",
    "包裝": "10毫升、50毫升小瓶裝 100支以下盒裝",
    "儲存溫度": "",
    "有效期間": "",
    "指示藥品審查基準": "",
    "標籤、仿單及包裝加註": "",
    "藥品類別": "05限由醫師使用",
    "管制藥品分類級別": "",
    "藥品分類": "",
    "監視期限": "",
    "主成分略述": "Rituximab",
    "限制項目": "02輸　入",
    "申請商名稱": "1903101100  台灣羅氏醫療診斷設備股份有限公司",
    "申請商地址": "台北市中山區民權東路3段2號10樓",
    "主製造廠": [
        {
            "製造廠名稱": "FDE0261000  ROCHE DIAGNOSTICS GMBH",
            "製造廠廠址": "SANDHOFER STRASSE 116 D-68305 MANNHEIM GERMANY",
            "製造廠公司地址": "",
            "製造廠國別": "GERMANY",
            "製程": ""
        }
    ],
    "次製造廠": [
        {
            "製造廠名稱": "FCH0208000  F.HOFFMANN-LA ROCHE LTD.",
            "製造廠廠址": "WURMISWEG, CH-4303 KAISERAUGST, SWITZERLAND",
            "製造廠公司地址": "",
            "製造廠國別": "SWITZERLAND",
            "製程": "包裝"
        },
        {
            "製造廠名稱": "FUS0767000  GENENTECH, INC.",
            "製造廠廠址": "1000 NEW HORIZONS WAY, VACAVILLE, CA 95688, USA",
            "製造廠公司地址": "",
            "製造廠國別": "UNITED STATES",
            "製程": "原料藥製造廠"
        },
        {
            "製造廠名稱": "FUS0768000  GENENTECH, INC.",
            "製造廠廠址": "1 ANTIBODY WAY, OCEANSIDE, CA 92056, USA",
            "製造廠公司地址": "",
            "製造廠國別": "UNITED STATES",
            "製程": "原料藥製造廠"
        }
    ],
    "CCC號列": "",
    "藥理治療分類": "",
    "ingredients": [
        {
            "成分類別": "主成分",
            "成分代碼": "1013002400",
            "成分名稱": "Rituximab",
            "含量描述": "",
            "含量": "10.0000000000",
            "單位": "MG"
        }
    ],
    "仿單外盒": [
        {
            "title": "100009480001-102-12-19.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60000948&Seq=001&Type=9"
        },
        {
            "title": "100009480006-102-12-19.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60000948&Seq=005&Type=8"
        }
    ]
}